INSIGHTS ON CLINICAL TRIAL DESIGN
-
![GettyImages-1132766141 patient recruitment]( "Recruiting & Retaining More Patients Per Site:")
Recruiting & Retaining More Patients Per Site:Through Home Trial Support (HTS) services, MRN is able to enhance the accessibility of clinical trials while reducing the emotional toll on their patients suffering from loss of mobility.
-
![GettyImages-1054148730-clinical-outsourcing-partner-FSP]( "How Mobile Clinics Advance Diversity In Clinical Research")
How Mobile Clinics Advance Diversity In Clinical ResearchMobile clinics reduce participation barriers, enable more inclusive trials, deliver representative data, speed timelines, and advance equity in research.
-
![Diversity]( "The Importance Of Diversity In Clinical Trials")
The Importance Of Diversity In Clinical TrialsA recent FDA draft guidance aims to address health disparities and enhance data quality with action plans for greater inclusivity in clinical trials. Explore practical steps to building trust and inclusivity in clinical research.
-
![Mural video]( "A Global Framework For Participant Engagement, Retention & Trial Success")
A Global Framework For Participant Engagement, Retention & Trial SuccessExplore how clinical operations leaders can close the global retention gap by designing experiences that feel genuinely local, from how participants are paid to how they’re supported day to day.
-
Creating Success With Digital Measures8/2/2024
Recent research from the Tufts Center for the Study of Drug Development (CSDD) illuminated the substantial ROI of digital endpoints in clinical trials. Discover how to transform your trials today.
-
Navigating The 7 Biggest Challenges In Rare Disease Clinical Trials4/11/2025
Discover how partnering with specialized rare disease CROs allows drug sponsors to accelerate treatment development, navigate trial complexities, and ultimately improve patient outcomes.
-
Cell And Gene Therapy Field Quiet In Q28/15/2024
While there weren't any new gene or cell therapy approvals in Q2 2024, the U.S. approved two RNA therapies: Rytelo, an oligonucleotide telomerase inhibitor, and mRESVIA, an mRNA vaccine.
-
Think U.S.A.: The Operations Behind Your Clinical Trials1/22/2025
Ready to think differently about early-phase clinical development? Check out the spotlight on our U.S. clinical facilities and the incredible teams behind them.
-
Cohort Configuration Feature Of An RTSM Platform3/16/2026
Master trial agility by building and prioritizing cohorts in real time. Effortlessly manage dose levels and enrollment limits to keep your study on track, even as protocols evolve.
CLINICAL TRIAL DESIGN SOLUTIONS
-
![GettyImages-1141567619 doctor patient]( "First In Human (FIH) Fact Sheet")
Altasciences has decades of experience designing, conducting, and reporting on first-in-human (FIH) clinical trials. For small or large molecules, simple or complex trials, we have the expertise, purpose-built Phase 1 facilities, and seamless processes to deliver quality with speed and ease.
-
![Clinicians doctors meeting iStock-1264556832]( "Think Bold. Think Scientific. Think Veristat.")
Veristat harnesses knowledge, expertise, and scale to provide superior solutions and progressive approaches to mitigate risks and achieve meaningful outcomes for biopharmaceutical and medical technology companies, and their patients.
-
![GettyImages-576902490 meeting presentation]( "Biotech-Tailored Clinical Development")
Strategic planning, data-driven decisions, and global coordination accelerate clinical timelines while ensuring quality. Explore risk-based monitoring and practical ways to overcome complexity.
-
![patient recruitment iStock-1299220556]( "Introducing Citeline PatientMatch: Precision Patient Recruitment")
The window for identifying the right patients to enroll in clinical trials is shrinking. With Citeline PatientMatch, sponsors can pinpoint eligible patients before a treatment plan is finalized.
-
![GettyImages-1354172647 research]( "IRB Services For Institutional Sites")
Advarra can serve as your partner for everything from single investigational sites to multisite research consortia and therapeutic networks.
